NEW YORK (GenomeWeb) – Horizon Discovery Group today announced it has signed a supply and licensing agreement with Adarza BioSystems, giving Horizon the exclusive right to offer research services on Adarza's Arrayed Imaging Reflectometry multiplex immunoassay technology.
Adarza's technology has the ability to detect hundreds of proteins in a single drop of blood, in sample volumes as low as 10 microliters and with sensitivities as low as 1 pg/mL the Rochester, N.Y.-based startup said in a statement. Current multiplex assay systems have difficulty detecting more than 30 analytes in a single sample, the firm added.
Horizon said that in 2015 it would launch a portfolio of products capable of detecting between 100 and 400 analytes, and it plans to offer custom assay development on the platform.
Preston Keller, VP of business development at Adarza, said access to Horizon's sales and marketing network would allow the firm "to bring the technology to market sooner and much more broadly than we could alone."
Cambridge, UK-based Horizon supplies tools for research in genomics and personalized medicine.
Financial terms of the deal were not disclosed.